What is the role of antiplatelet therapy in the treatment of CREST syndrome?

Updated: Oct 05, 2020
  • Author: Jeanie C Yoon, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print

Antiplatelet therapy has had mixed results. Ticlopidine showed benefit in one case and was ineffective in another study. [94] Clopidogrel has not been studied in Raynaud phenomenon. Cilostazol has shown some benefit in open-label trials, and a recent double-blinded randomized trial showed that it significantly increased the mean brachial artery diameter; however, the patient's subjective symptoms did not appear to improve. [95, 96] Recombinant tissue plasminogen activator produces only transient improvement in blood flow in patients with digital ischemia and is not recommended for Raynaud phenomenon. [97]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!